Filing Details
- Accession Number:
- 0001209191-12-042551
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-17 20:19:13
- Reporting Period:
- 2012-08-16
- Filing Date:
- 2012-08-17
- Accepted Time:
- 2012-08-17 20:19:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1208907 | G Thomas Wiggans | C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-16 | 10,000 | $25.30 | 20,065 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-16 | 10,000 | $68.63 | 10,065 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-08-16 | 2,000 | $68.60 | 8,065 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-08-16 | 10,000 | $0.00 | 10,000 | $25.30 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
10,000 | 2015-03-09 | No | 4 | M | Direct |
Footnotes
- The shares were sold between $68.54 and $68.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The shares were sold between $68.56 and $68.6233. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Fully vested.